Neurobo Pharmaceuticals Stock Probability of Future Stock Price Finishing Under 0.02
| NRBO Stock | USD 2.37 0.02 0.85% |
Neurobo |
Neurobo Pharmaceuticals Target Price Odds to finish below 0.02
The tendency of Neurobo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.02 or more in 90 days |
| 2.37 | 90 days | 0.02 | near 1 |
Based on a normal probability distribution, the odds of Neurobo Pharmaceuticals to drop to $ 0.02 or more in 90 days from now is near 1 (This Neurobo Pharmaceuticals probability density function shows the probability of Neurobo Stock to fall within a particular range of prices over 90 days) . Probability of Neurobo Pharmaceuticals price to stay between $ 0.02 and its current price of $2.37 at the end of the 90-day period is about 7.56 .
Given the investment horizon of 90 days Neurobo Pharmaceuticals has a beta of 0.0343. This indicates as returns on the market go up, Neurobo Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Neurobo Pharmaceuticals will be expected to be much smaller as well. Additionally Neurobo Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Neurobo Pharmaceuticals Price Density |
| Price |
Predictive Modules for Neurobo Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neurobo Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Neurobo Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neurobo Pharmaceuticals is not an exception. The market had few large corrections towards the Neurobo Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neurobo Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neurobo Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.58 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 0.46 | |
Ir | Information ratio | -0.14 |
Neurobo Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurobo Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurobo Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Cardiometabolic Diseases |
Neurobo Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neurobo Stock often depends not only on the future outlook of the current and potential Neurobo Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurobo Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.1 M | |
| Cash And Short Term Investments | 22.4 M |
Neurobo Pharmaceuticals Technical Analysis
Neurobo Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Neurobo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Neurobo Pharmaceuticals. In general, you should focus on analyzing Neurobo Stock price patterns and their correlations with different microeconomic environments and drivers.
Neurobo Pharmaceuticals Predictive Forecast Models
Neurobo Pharmaceuticals' time-series forecasting models is one of many Neurobo Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Neurobo Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Neurobo Pharmaceuticals
Checking the ongoing alerts about Neurobo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Neurobo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Cardiometabolic Diseases |
Check out Neurobo Pharmaceuticals Backtesting, Neurobo Pharmaceuticals Valuation, Neurobo Pharmaceuticals Correlation, Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Volatility, Neurobo Pharmaceuticals History as well as Neurobo Pharmaceuticals Performance. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.